Skip to main content
editor@jprims.in
9343055451
e-ISSN: 3049-1681
Journal of Pharmaceutical Research and Integrated Medical Sciences

Journal of Pharmaceutical Research and Integrated Medical Sciences

Deleshwar Kumar

Author Profile
Kamla Institute of Pharmaceutical Sciences, Shri Shankaracharya Professional University, Junwani, Bhilai, Chhattisgarh, India
3
Publications
1
Years Active
8
Collaborators
157
Citations

Publications by Deleshwar Kumar

3 publications found • Active 2026–2026

2026

3 publications

Ethanolic Leaf Extract of Chenopodium album Linn. Attenuates Calcium Oxalate-Associated Urolithiasis in Rats: An Integrated In Vitro and In Vivo Evaluation

with Arpan Kumar Tripathi, Yashika
11/17/2026
pp. 27-40

Background: The primary stone component in urolithiasis, a recurrent urinary tract disease characterized by crystal nucleation, development, aggregation, and retention, is calcium oxalate (CaOx). Chenopodium album Linn. has a long history of ethnomedical use for urinary and renal issues and has demonstrated an initial anti-crystallization effect. However, little information is known about the relationship between in vivo renal and urinary outcomes and in vitro CaOx crystallization. Objective: This study evaluated the anti-urolithiatic potential of an ethanolic leaf extract of C. album (EECA) using complementary in vitro and in vivo techniques. Methods: The leaves were subjected to Soxhlet extraction using ethanol to obtain a 6.0% w/w extract, and preliminary phytochemical screening was carried out. The nucleation of CaOx was measured at 10–100 mg/mL, and the inhibition of crystal growth was also examined. The standard treatment was cystone (750 mg/kg). EECA was given at doses of 50 and 200 mg/kg to rats with urolithiasis associated with calcium oxalate. Urinary uric acid, urine volume, and renal histology were determined. Results: EECA inhibited CaOx nucleation in a concentration-dependent manner by 18.75% at 10 mg/mL and 77.50% at 100 mg/mL. Inhibition at 100 mg/mL exceeded the observed Cystone response of 72.50%. EECA also raised urine production and reduced urinary uric acid, particularly at 200 mg/kg. The results of the histopathology showed improved kidney structure. Conclusion: EECA demonstrated anti-crystallization and protective qualities in experimental urolithiasis, encouraging further mechanistic, phytochemical-standardizing, and translational research.

Nanotechnology-Augmented Herbal Remedies and Synthetic Substances for Leishmaniasis: An In-Depth Review of Promising Solutions

with Dr Saurabh Shrivastava
9/7/2026
pp. 20-57

Background: Visceral leishmaniasis (VL), the deadliest form of leishmaniasis, remains endemic in tropical/subtropical regions. Conventional treatments are limited by toxicity, high cost, and emerging drug resistance. Methods: Studies published between 2000–2024 on antileishmanial efficacy of herbal extracts, synthetic drugs, and nanoformulations (liposomes, polymeric nanoparticles, metallic nanocarriers) were analyzed via databases including PubMed, Scopus, and Web of Science following PRISMA guidelines. Results: Gold-standard therapies like liposomal amphotericin‑B (AmBisome®) remain vital but require improved targeting and reduced toxicity. Phytocompounds from Azadirachta indica, Curcuma longa, and Withania somnifera exhibit significant in vitro/in vivo antileishmanial activity. Nanocarriers—liposomes, solid-lipid NPs, polymeric dendrimers, metallic nanoparticles—enhance bioavailability, reduce off‑target effects, and support targeted macrophage uptake. Patents focus on curcumin‑PLGA systems, dendrimer‑mediated combination therapies, and ligand-targeted delivery. Conclusion: Integrating low‑toxicity phytochemicals with nanotechnology platforms offers a promising, next-generation approach to treat VL. Future preclinical standardization and clinical trials are urgently needed. Graphical Abstract

Neuropharmacology of Novel Antipsychotics: Mechanisms, Efficacy, and Future Directions

with Devendra Kumar Sahu Sahu, Neha Mandle Mandle, Gautam Dansena Dansena, Harsh Kumar Tamrakar Tamrakar, Deleshwar Kumar Kumar
2026
pp. 1-14

D₂ antagonism toward multimodal receptor targeting, glutamatergic modulation, and neuroinflammatory regulation. Despite the success of atypical antipsychotics, limitations such as metabolic side effects, cognitive deficits, and treatment resistance persist. Novel compounds—including third-generation antipsychotics, trace amine-associated receptor 1 (TAAR1) agonists, serotonin–dopamine activity modulators (SDAMs), and glutamatergic agents—are redefining psychopharmacology through receptor-biased signaling, synaptic plasticity enhancement, and neuroimmune modulation. This review consolidates current insights into the neuropharmacological mechanisms of emerging antipsychotics, compares their efficacy and safety profiles, and explores future directions in precision psychiatry, AI-based drug design, and neurocircuit-level therapeutics.